References
- Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep 2003; 2: 202–208
- McCollum A, Bigelow C L, Elkins S L, Hardy C L, Files J C. Unusual skin lesions in chronic myelomonocytic leukemia. South Med J 2003; 96: 681–684
- Doutre M S, Beylot C, Bioulac P, de Mascarel A. Skin presentation of chronic myelomonocytic leukaemia resembling cutaneous lymphomas. J R Soc Med 1990; 83: 593–594
- Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 1996; 88: 2480–2487
- Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57
- Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713–717